Eli Lilly and Co. and Amylin Pharmaceuticals have another reason to celebrate this morning. The companies released a statement claiming that the powerful Committee for Medicinal Products for Human Use of the European Medicines Evaluation Agency has issued a positive response recommending approval for their new diabetes treatment Exenatide.
Exenatide, more commonly known as Byetta, will be marketed in Europe under the Byetta brand name. Under this name the drug has been enormously successful in the United States, selling innumerable units. The drug gained considerable exposure, media attention and hence sales when it was revealed that consistent use causes weight loss, a key consideration for many diabetics .
Amylin and Eli Lilly are looking to get Exenatide approved as an adjunctive therapy to improve blood sugar control amongst patients who have type 2 diabetes. Some type 2 diabetics have problems with current oral diabetes medication, and the two companies are hoping that Byetta will fill this breach.
Byetta, already becoming a blockbuster drug, is likely to go from strength to strength in the future.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…